BREANA BAKER: Open Payments
NPI 1285215541 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,636 in 72 payments from 14 companies in 2025. Trend: 2023 $2,652 · 2024 $3,939 · 2025 $1,636
Food & beverage: $1,534Education: $102
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 12 | $252 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $236 |
| ABBVIE INC. | 13 | $198 |
| Phathom Pharmaceuticals, Inc. | 3 | $169 |
| Madrigal Pharmaceuticals | 6 | $145 |
| Janssen Biotech, Inc. | 2 | $102 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $100 |
| Gilead Sciences, Inc. | 4 | $100 |
| Ardelyx, Inc. | 5 | $98 |
| QOL Medical, LLC | 3 | $82 |
Products named: DUPIXENT, ENTYVIO, VOQUEZNA, REZDIFFRA, TREMFYA, IBSRELA, Sucraid, RINVOQ.
Industry payments across AZ — which companies pay providers there.
